iShares US Aerospace & Defense ETF vs Nuwellis Inc — how do they compare? iShares US Aerospace & Defense ETF trades at $206.55 (market cap $11.87B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares US Aerospace & Defense ETF is far larger — about 5395.5× Nuwellis Inc's market cap, and iShares US Aerospace & Defense ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Aerospace & Defense ETF for 19 Days and Nuwellis Inc for 26 Days on average.
| ITA | NUWE | |
|---|---|---|
Market Cap | $11.87B | $2.20M |
Volume | 1,060,125 | 121,544 |
Sector | Sector/Thematic | Health |
52-Week High | $253.22 | $146.65 |
52-Week Low | $198.23 | $0.68 |
Typical Hold Time | 19 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
iShares U.S. Aerospace & Defense ETF seeks to track U.S. companies in the aerospace and defense sector. Its holdings include manufacturers of commercial and military aircraft, defense systems, and related equipment.
Read more on ITA →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →